Market closed

Neuropace/$NPCE

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Neuropace

NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.

Ticker

$NPCE

Sector

Health Care

Trading on

NASDAQ

Industry

Health Care Equipment & Supplies

Headquarters

Mountain View, United States

Employees

184

Website

www.neuropace.com

Neuropace Metrics

BasicAdvanced

$361M

-

-$0.99

2.06 -

Price and volume

Market cap

$361M

Beta

2.06

52-week high

$18.15

52-week low

$5.45

Average daily volume

77K

Financial strength

Current ratio

5.588

Quick ratio

4.627

Long term debt to equity

729.909

Total debt to equity

748.234

Interest coverage (TTM)

-2.61%

Management effectiveness

Return on assets (TTM)

-14.74%

Return on equity (TTM)

-214.55%

Valuation

Price to revenue (TTM)

4.491

Price to book

36.71

Price to tangible book (TTM)

36.71

Price to free cash flow (TTM)

-20.445

Growth

Revenue change (TTM)

27.00%

Earnings per share change (TTM)

-33.71%

3-year revenue growth (CAGR)

19.38%

3-year earnings per share growth (CAGR)

-29.53%

What the Analysts think about Neuropace

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Neuropace stock.

Neuropace Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Neuropace Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Neuropace News

AllArticlesVideos

NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024 and Provides Business Updates

GlobeNewsWire·7 days ago

NeuroPace to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewsWire·4 weeks ago

NeuroPace to Host Investor Day on January 28th in New York City

GlobeNewsWire·1 month ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NPCE

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Neuropace stock?

Neuropace (NPCE) has a market cap of $361M as of January 15, 2025.

What is the P/E ratio for Neuropace stock?

The price to earnings (P/E) ratio for Neuropace (NPCE) stock is 0 as of January 15, 2025.

Does Neuropace stock pay dividends?

No, Neuropace (NPCE) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Neuropace dividend payment date?

Neuropace (NPCE) stock does not pay dividends to its shareholders.

What is the beta indicator for Neuropace?

Neuropace (NPCE) has a beta rating of 2.06. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.